Ipsen in Ireland
Development and manufacturing
The Dublin site, which opened in 1989, is the Group’s center for the production and development of peptides (lanreotide and triptorelin). In addition to the development of peptide active ingredients, Dublin also has responsibility for developing small molecule active ingredients, in particular with regard to the development of manufacturing processes, large-scale manufacturing, quality control and analytic development.
Message from the chairman
3 questions to Marc de Garidel, Chairman & CEO
07 February 2014 - Paris (France)
Ipsen announces positive top line results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered…